[Efficacy Analysis of Unrelated Cord Blood Transplantation for High-Risk Refractory AML1-ETO Positive Myeloid Leukemia].

Autor:	Ren JR; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Zhu XY; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Tang BL; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Wan X; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Tong J; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Zhang L; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Zhang XH; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Song KD; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Yao W; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Sun GY; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China., Liu HL; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China,E-mail: 13866771269@163.com., Sun ZM; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui province, China.
Jazyk:	čínština
Zdroj:	Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2019 Aug; Vol. 27 (4), pp. 1246-1252.
DOI:	10.19746/j.cnki.issn.1009-2137.2019.04.042
Abstrakt:	Objective: To analyze the clinical outcomes of engraftment, graft-versus-host disease (GVHD) and survival in the patients with AML1-ETO positive acute myeloid leukemia (AML) treated with unrelated umbilical cord blood transplantation (UCBT). Methods: Forty-Five patients with high-risk refractory AML1-ETO positive AML were treated with a single UCBT in a single center from July 2010 to April 2018. All the patients underwent a myeloablative preconditioning regimen，and cyclosporine A (CSA) combined with mycophenolate mofetil (MMF) was used to prevent GVHD. Results: The median value of total nucleated cells (TNC) in cord blood was 5.21 (1.96-12.68)×10 7 /kg recipient body weight, and that of CD34+ cells was 5.61 (0.56-15.4)×10 5 /kg recipient weight. The implantation rate of neutrophil at 42 d and that of platelet at 120 d were 95.6% and 86.7%, respectively. The median time of absolute neutrophil count (ANC)＞0.5×10 9 /L and platelet 20×10 9 /L were 16 (12-18) d and 37 (17-140) d after transplantation, respectively. The cumulative incidence of Ⅰ -Ⅳ grade acute GVHD (aGVHD) at 100 d after transplantation was 48.9% (95% CI 33.5%-62.6%), Ⅱ-Ⅳ grade aGVHD occurred in 12 cases (33.3%) (95% CI 20%-47.2%) , and Ⅲ-Ⅳ grade a GVHD in 8 cases (20%) (95% CI 9.8% -32.8%). In 5 cases of 40 patients survived over 100 days, the chronic GVHD (cGVHD) occurred after transplantation, among which 4 were localized, and 1 was extensive. 3 patients relapsed, and the 2-year cumulative relapse rate was 9.5% (95% CI 2.4%-22.8%). The median follow-up time was 23.5 (0.9-89.67) months, 10 patients died, 2-year disease-free survival rate (DFS) was 72.7%, and overall survival rate (OS) was 75.5%. Multivariate analysis showed that Ⅲ-Ⅳ. acute GVHD (aGVHD) affected overall survival. Conclusion: UCBT is an effective rescue treatment for patients with high-risk refractory AML1-ETO positive AML.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu